A Phase 3 interventional study of Febuxostat and Febuxostat in Gout, sponsored by Takeda. Completed. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2010-07-27.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing febuxostat in Gout — 1 open to participants now, 1 under way, none of them phase 3. Febuxostat · Gout.
Among the 29 studies testing febuxostat in Gout, this one is the 3rd largest by enrollment, is one of 2 that started in 2003, is one of 10 in phase 3, and was the 4th registered.
347 studies on the registry are indexed under Gout; 50 are open to participants now.
Browse Gout studies →1 of the 29 studies testing febuxostat in Gout is open now. Recruiting first, the newest first:
Haiphong University of Medicine and Pharmacy
Healthy volunteers
Febuxostat: first FDA approval 2009 (ULORIC), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,086 is above the median of 83 across 288 interventional studies indexed under Gout.
Median enrollment 109 across the 29 interventional studies. Of the 27 that completed or were terminated, 18 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 29 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
15 studies in Gout by Takeda: none open now, none under way, none of them phase 3. Of 15 finished, 14 (93%) have results posted.
Among the 15 studies in Gout by Takeda, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2003, is one of 6 in phase 3, and was the 4th registered.
Takeda’s Gout studies by the year they started, since 2001.
1 of the studies testing febuxostat in Gout that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07369622Haiphong University of Medicine and PharmacyHLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness | 2027-06-20 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies testing febuxostat in Gout, from their registry updates:
Among Takeda’s 15 in Gout:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the long-term safety of febuxostat, once daily (QD), compared to allopurinol in reducing serum urate levels in subjects with gout.
Uric acid is the end product of purine degradation in humans. Hyperuricemia, a urate concentration in serum exceeding the limit of urate solubility (approximately 7.0 mg/dL), is a common biochemical abnormality. Aberrations in any of the multiple mechanisms involved in the production and/or excretion of uric acid may increase serum urate concentrations, with persistent hyperuricemia as a marker for extracellular fluid monosodium urate supersaturation. As such, hyperuricemia is a necessary (but often insufficient) risk factor for monosodium urate crystal deposition in tissues and is the fundamental pathophysiological process underlying the clinical manifestations of gout, which is a chronic disease characterized by urate crystal formation and deposition in joints and bones. Gout may progress from episodic attacks of acute inflammatory arthritis to a disabling chronic disorder characterized by deforming arthropathy; destructive deposits of urate crystals (tophi) in bones, joints, and other organs; structural and functional renal impairment due to interstitial urate crystal deposition; and urinary tract stones composed entirely or partially of uric acid crystals. Management of gout requires chronic treatment aimed at lowering serum urate levels into a subsaturating range (usually \<6.0 mg/dL) in which crystal formation and deposition are prevented or reversed.
Febuxostat (TMX-67) is a non-purine selective xanthine oxidase inhibitor being developed as an orally administered agent for the management of hyperuricemia in patients with gout.
This study was originally designed and initiated having all subjects initially assigned to 80 mg febuxostat provided as an 80 mg tablet, to be administered orally. Subjects could be titrated to 120 mg, provided as one 40 and 80 mg tablet, between Months 2 and 6, if their serum uric acid rose > 6.0 mg/dL; the dose could be down-titrated to 80 mg if the serum uric acid decreased to \< 3.0 mg/dL.
The protocol was amended to add a comparator arm, and to have subjects randomized to 80 or 120 mg febuxostat or allopurinol (100 or 300 mg, dependent on renal function). The information below reflects the treatments following the implementation of the revised protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Febuxostat
Drug: Febuxostat
Drug: Allopurinol
Febuxostat 80 mg, tablets, orally, once daily.
Also known as: TMX-67, Tei-6720, Uloric
Febuxostat 120 mg, tablets, orally, once daily.
Also known as: TMX-67, Tei-6720, Uloric
Allopurinol 100 mg or 300 mg, tablets, orally, once daily.
Also known as: Zyloprim
Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1.
Serum urate values were obtained at the Month 1 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 1 visit was summarized.
Time frame: Month 1
Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 12.
Serum urate values were obtained at the Month 12 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 12 visit was summarized.
Time frame: Month 12
Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 24.
Serum urate values were obtained at the Month 24 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 24 visit was summarized.
Time frame: Month 24
Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 36.
Serum urate values were obtained at the Month 36 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 36 visit was summarized.
Time frame: Month 36
Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Last Visit on Treatment.
The percentage of subjects whose serum urate was \<6.0 mg/dL at the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment.
Time frame: Last Visit on treatment (up to 40 months).
Percent Change in Serum Urate Levels From Baseline to the Last Visit on Treatment.
The percent change in serum urate from baseline to the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment.
Time frame: Last Visit on treatment (up to 40 months).
Percent Change From Baseline in Primary Tophus Size at Month 12 for Subjects With Palpable Tophi Measured at Baseline.
The area of the primary tophus was calculated based on the length and width of the tophus measured at the Month 12 visit. The percent change from baseline in primary tophus size to the Month 12 visit was summarized.
Time frame: Month 12
Percent Change From Baseline in Primary Tophus Size at Month 24 for Subjects With Palpable Tophi Measured at Baseline.
The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 24 visit. The percent change from baseline in primary tophus size to the Month 24 visit was summarized.
Time frame: Month 24
Percent Change From Baseline in Primary Tophus Size at Month 36 for Subjects With Palpable Tophi Measured at Baseline.
The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 36 visit. The percent change from baseline in primary tophus size to the Month 36 visit was summarized.
Time frame: Month 36
Percent Change From Baseline in Primary Tophus Size at Final Visit for Subjects With Palpable Tophi Measured at Baseline.
The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and final visit. The percent change from baseline in primary tophus size to the final visit was summarized.
Time frame: Final Visit (up to 40 months).
Percent Change From Baseline in the Total Number of Tophi for Subjects With Palpable Tophi at Final Visit.
The number of tophi were counted at baseline and final visits. The percent change from baseline in the number of tophi to the final visit was summarized.
Time frame: Final Visit (up to 40 months).
Percentage of Subjects Requiring Treatment for Gout Flare up to Month 12.
The percentage of subjects requiring treatment for gout flare during the first twelve months of final stable treatment was summarized.
Time frame: Month 12
Percentage of Subjects Requiring Treatment for Gout Flare After Month 12.
The percentage of subjects requiring treatment for gout flare after the first 12 months of final stable treatment was summarized.
Time frame: After Month 12 to Final Visit
Subjects were enrolled at 174 investigative sites, including 168 in the United States and 6 in Canada, from 28 July 2003 to 26 February 2007.
| Milestone | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD |
|---|---|---|---|
| Started | 606 | 388 | 92 |
| Completed | 412 | 217 | 35 |
| Not completed | 194 | 171 | 57 |
| Withdrew: Adverse event | 54 | 22 | 2 |
| Withdrew: Protocol violation | 6 | 3 | 3 |
| Withdrew: Lost to follow-up | 42 | 39 | 9 |
| Withdrew: Did not continue under amendment 4 | 1 | 1 | 2 |
| Withdrew: Personal reason(s) | 39 | 31 | 8 |
| Withdrew: Therapeutic failure | 10 | 38 | 22 |
| Withdrew: Gout flare | 2 | 3 | 0 |
| Withdrew: Reason not specified | 40 | 34 | 11 |
The percent change in serum urate from baseline to the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment.
| percent change from baseline | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD |
|---|---|---|---|
| Percent Change in Serum Urate Levels From Baseline to the Last Visit on Treatment. | -46.69 ± 17.43 | -52.99 ± 19.12 | -32.17 ± 17.71 |
The area of the primary tophus was calculated based on the length and width of the tophus measured at the Month 12 visit. The percent change from baseline in primary tophus size to the Month 12 visit was summarized.
| percent change from baseline | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD |
|---|---|---|---|
| Percent Change From Baseline in Primary Tophus Size at Month 12 for Subjects With Palpable Tophi Measured at Baseline. | -82 (-100 to -40) | -79 (-100 to -26) | -56 (-100 to -16) |
Serum urate values were obtained at the Month 1 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 1 visit was summarized.
| percentage of subjects | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD |
|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1. | 80.8 | 87.0 | 46.0 |
Serum urate values were obtained at the Month 12 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 12 visit was summarized.
| percentage of subjects | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD |
|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 12. | 88.9 | 86.3 | 82.2 |
Serum urate values were obtained at the Month 24 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 24 visit was summarized.
| percentage of subjects | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD |
|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 24. | 89.3 | 87.2 | 78.6 |
Serum urate values were obtained at the Month 36 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Month 36 visit was summarized.
| percentage of subjects | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD |
|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 36. | 90.8 | 91.5 | 90.0 |
The percentage of subjects whose serum urate was \<6.0 mg/dL at the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment.
| percentage of subjects | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD |
|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Last Visit on Treatment. | 70.8 | 82.0 | 32.6 |
The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 24 visit. The percent change from baseline in primary tophus size to the Month 24 visit was summarized.
| percent change from baseline | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD |
|---|---|---|---|
| Percent Change From Baseline in Primary Tophus Size at Month 24 for Subjects With Palpable Tophi Measured at Baseline. | -100 (-100 to -54) | -96 (-100 to -52) | -87 (-98 to -29) |
The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 36 visit. The percent change from baseline in primary tophus size to the Month 36 visit was summarized.
| percent change from baseline | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD |
|---|---|---|---|
| Percent Change From Baseline in Primary Tophus Size at Month 36 for Subjects With Palpable Tophi Measured at Baseline. | -83 (-83 to -83) | — | — |
The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and final visit. The percent change from baseline in primary tophus size to the final visit was summarized.
| percent change from baseline | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD |
|---|---|---|---|
| Percent Change From Baseline in Primary Tophus Size at Final Visit for Subjects With Palpable Tophi Measured at Baseline. | -96 (-100 to -42) | -84 (-100 to -16) | -67 (-100 to 0) |
The number of tophi were counted at baseline and final visits. The percent change from baseline in the number of tophi to the final visit was summarized.
| percent change from baseline | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD |
|---|---|---|---|
| Percent Change From Baseline in the Total Number of Tophi for Subjects With Palpable Tophi at Final Visit. | -59.9 ± 45.9 | -58.3 ± 42.5 | -48.7 ± 42.5 |
The percentage of subjects requiring treatment for gout flare during the first twelve months of final stable treatment was summarized.
| percentage of subjects | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD |
|---|---|---|---|
| Percentage of Subjects Requiring Treatment for Gout Flare up to Month 12. | 29.4 | 42.5 | 28.3 |
The percentage of subjects requiring treatment for gout flare after the first 12 months of final stable treatment was summarized.
| percentage of subjects | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD |
|---|---|---|---|
| Percentage of Subjects Requiring Treatment for Gout Flare After Month 12. | 15.3 | 19.8 | 23.2 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Febuxostat 80 mg QD | — | 98/801 (12.2%) | 444/801 (55.4%) |
| Febuxostat 120 mg QD | — | 50/487 (10.3%) | 257/487 (52.8%) |
| Allopurinol QD | — | 16/178 (9%) | 66/178 (37.1%) |
| Event | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD |
|---|---|---|---|
| Ischaemic Coronary Artery DisordersCardiac disorders | 17/801 | 3/487 | 2/178 |
| Coronary Artery Disorders not elsewhere classified (NEC)Cardiac disorders | 13/801 | 6/487 | 1/178 |
| Abdominal and Gastrointestinal InfectionsInfections and infestations | 3/801 | 2/487 | 2/178 |
| Spine and Neck DeformitiesMusculoskeletal and connective tissue disorders | 1/801 | 0/487 | 2/178 |
| Cholecystitis and CholelithiasisHepatobiliary disorders | 7/801 | 1/487 | 1/178 |
| Lower Respiratory Tract and Lung InfectionsInfections and infestations | 7/801 | 2/487 | 0/178 |
| OsteoarthropathiesMusculoskeletal and connective tissue disorders | 3/801 | 4/487 | 0/178 |
| Central Nervous System Haemorrhages and CVANervous system disorders | 6/801 | 2/487 | 0/178 |
| Infections NECInfections and infestations | 5/801 | 0/487 | 0/178 |
| Pulmonary Thrombotic and Embolic ConditionsRespiratory, thoracic and mediastinal disorders | 5/801 | 0/487 | 1/178 |
| Event | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD |
|---|---|---|---|
| Upper Respiratory Tract InfectionsInfections and infestations | 246/801 | 119/487 | 30/178 |
| Musculoskeletal and Connective Tissues Signs and Symptoms NECMusculoskeletal and connective tissue disorders | 140/801 | 82/487 | 23/178 |
| Joint Related Signs and SymptomsMusculoskeletal and connective tissue disorders | 100/801 | 50/487 | 12/178 |
| Vascular Hypertensive Disorders NECVascular disorders | 67/801 | 41/487 | 5/178 |
| Headache NECNervous system disorders | 45/801 | 38/487 | 7/178 |
| Lower Respiratory Tract and Lung InfectionsInfections and infestations | 60/801 | 27/487 | 6/178 |
| Diarrhoea (Excl Infective)Gastrointestinal disorders | 38/801 | 33/487 | 4/178 |
| Oedema NECGeneral disorders | 49/801 | 17/487 | 3/178 |
| Influenza Viral InfectionsInfections and infestations | 44/801 | 16/487 | 2/178 |
| Dermatitis and EczemaSkin and subcutaneous tissue disorders | 44/801 | 23/487 | 2/178 |
| Age Continuous(years) | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD | Total |
|---|---|---|---|---|
| Mean | 53.0 ± 11.74 | 48.4 ± 11.02 | 51.3 ± 12.72 | 51.2 ± 11.76 |
| Sex: Female, Male(Participants) | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD | Total |
|---|---|---|---|---|
| Female | 25 | 17 | 2 | 44 |
| Male | 581 | 371 | 90 | 1042 |
| Presence of Tophus(participants) | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD | Total |
|---|---|---|---|---|
| Present | 116 | 83 | 15 | 214 |
| Absent | 490 | 305 | 77 | 872 |
| Race/Ethnicity(participants) | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD | Total |
|---|---|---|---|---|
| Asian | 15 | 9 | 4 | 28 |
| Black or African American | 47 | 33 | 16 | 96 |
| White | 499 | 299 | 64 | 862 |
| Hispanic | 30 | 29 | 7 | 66 |
| Other | 15 | 18 | 1 | 34 |
| Renal Function(participants) | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD | Total |
|---|---|---|---|---|
| Normal | 593 | 381 | 92 | 1066 |
| Impaired | 13 | 7 | 0 | 20 |
| Body Mass Index (BMI)(kg/m²) | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD | Total |
|---|---|---|---|---|
| Mean | 31.9 ± 5.49 | 34.1 ± 6.71 | 32.4 ± 5.58 | 31.9 ± 5.49 |
| Serum Urate(mg/dL) | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Allopurinol QD | Total |
|---|---|---|---|---|
| Mean | 9.65 ± 1.20 | 10.05 ± 1.29 | 9.83 ± 1.27 | 9.81 ± 1.25 |
No study locations are listed for this record.
The record gives a start of Jul 2003, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2009, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Febuxostat